We are live on ! Find out more
BLRX icon

BioLineRX

29 hedge funds and large institutions have $1.75M invested in BioLineRX in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

106% more call options, than puts

Call options by funds: $451K | Put options by funds: $219K

0% more funds holding

Funds holding: 29 → 29 (0)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

0.66% less ownership

Funds ownership: 2.2% → 1.54% (-0.66%)

40% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 10

57% less capital inflows, than outflows

Capital inflows: $325K | Capital outflows: $761K

Holders
29
Holders Change
–
Holders Change %
0%
% of All Funds
0.42%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
6
Reduced
10
Closed
3
Calls
$451​K
Puts
$219​K
Net Calls
+$232​K
Net Calls Change
+$312​K

BLRX Hedge Fund Activity: Q4 2023 in Review

29 of the 6,880 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q4 2023, worth a combined $1.75M — down 29% from $2.46M a quarter earlier.

Fund positioning in BLRX was balanced in Q4 2023: 3 funds opened new positions, 3 closed out, 6 added to existing stakes and 10 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $96.7K. The largest seller was Sabby Management, exiting entirely with an estimated $382K sold.

  • 29 institutional investors held BioLineRX (BLRX) as of Q4 2023, unchanged from Q3 2023.
  • Funds reported $1.75M of BioLineRX stock for Q4 2023, down 29% quarter-over-quarter.
  • 3 funds opened new BioLineRX positions in Q4 2023 and 3 closed out, a net change of 0 holders.
  • The largest BioLineRX buyer in Q4 2023 was Morgan Stanley, an estimated $96.7K added.
  • The largest BioLineRX seller in Q4 2023 was Sabby Management, an estimated $382K sold.

Based on aggregated 13F filings for Q4 2023.